SK bioscience Files for First-in-Human Trial of Universal Coronavirus Vaccine (Pan-sarbecovirus Vaccine) GBP511 Phase 1/2 study in Australia
- Written by PR Newswire Asia - News Pronto RSS
 |
- Candidate designed to protect against COVID-19 variants and broader Sarbecoviruses
- Phase 1/2 study to enroll ~500 healthy adults, with topline results expected by 2028
- We aim to build a universal Sarbecovirus vaccine platform to proactively address future pandemics
SEONGNAM, South Korea, Oct. 15, 2025 /PRNewswire/ -- SK bioscience announced that...